Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib and Gemcitabine for Metastatic Pancreatic Cancer
NCT00161213Phase 2Completed
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Sep 2005
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in pancreatic cancer (PC), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Progression-free Survival at 4 years. Started Sep 2005; status: completed.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00161213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161213.